Mepivacaine Hydrochloride

盐酸甲哌卡因

Report date: 2025/01/07 14:46:51
NME

Base Information

Drug NameMepivacaine Hydrochloride
Drug Alias Name盐酸卡波卡因MepiGelMepicainMepivamolPolocaine +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockers
TargetsSodium channel alpha subunit
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeAcute PainBrachial Plexus Neuropathies +[5] 
Global Approved IndicationsAnesthesia
Approved Indications in ChinaAnesthesia
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesEUMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalWashington University School Of MedicineSandoz Ltd +[4] 
Inactive CompaniesHospira IncShandong Bestcomm Pharmaceutical Company Ltd
Active IndicationsPost-Acute COVID-19 SyndromeAcute PainAnesthesia
Inactive IndicationsBrachial Plexus NeuropathiesPeripheral Nervous System Diseases

Other Information

ATC CodeN01BB03
Related LinksWikipediaDrugBankKEGG